Tags

Q&A with Sean McCarthy Global Market Manager, Biologics, SCIEX MAM is an acronym for Multiple Attribute Method. In short, MAM is a method which may be applied for characterization of a biotherapeutic to understand its sequence, identify liabilities, identify...

As interest in N-glycan analysis grows within the biopharma industry, innovation continues allowing analyses to be done in less time with fewer and less tedious, sample preparation steps. One of these recent innovations was the release of the SCIEX Fast Glycan...

In a previous blog, we learned how you could Simplify Your Life with a Streamlined Workflow for Multiple Attribute Methodology (MAM). Based on the well-known technique of peptide mapping, a Liquid Chromatography-Mass Spectrometry-based MAM workflow (LC-MS MAM) enables...

When All You Need Is Range – Mass Range, Dynamic Range, and the Complete Range Launching the best possible product in the shortest time possible is key for pharmaceutical companies like you. As you know, nearly every process throughout the biologics development cycle...

Why LC-MS MAM?The Liquid Chromatography-Mass Spectrometry Multiple Attribute Methodology (LC-MS MAM) is a technique that is quickly gaining traction in the development and manufacturing of biopharmaceuticals. But what exactly is MAM? As researchers describe in a...

The effort to fully characterize and release a biotherapeutic to the market can be onerous. Typically, many tests are required to identify and monitor various attributes of the final product in order to ensure the safety and efficacy of the drug. These product quality...

Biopharmaceutical development is booming and now an integral part of many pharmaceutical company pipelines. While these emerging biologics present exciting opportunities for the industry, their sophistication is challenging the limits of characterization at all stages of discovery and development.

The quantitation of proteins using the surrogate peptide approach can complicate nominal mass Triple Quadrupole MRM measurements due to co-extracted interference when using non-selective extraction techniques such as pellet digestion. High resolution coupled with accurate mass filtering can mitigate such interference, as reported previously for the determination of rituximab using the TripleTOF 6600 (Protein Quant Approaches). However, an additional level of selectivity can often be achieved on nominal mass systems using the orthogonal gas-phase separation approach offered by the SelexION+® Differential Mobility System technology (DMS). Interfaced between the sampling orifice and ion source, the DMS separates ions based upon differences in their migration rates under alternating low and high field waveform amplitudes (Figure 1). Ion clustering in low fields and declustering in high fields amplifies the distinction in mobility of an ion, resulting in improved resolution from interfering species of differing molecular cross-section.1-4

The number of protein based drugs coming onto the market is at an all-time high, particularly those produced with a host cell system. With host cells come their own proteins. These host cell proteins (HCPs) constitute a major part of process-related impurities and can adversely affect drug safety, so it is critical that they are identified and quantified accurately.

Characterization and quantification of host cell proteins (HCPs) in biopharmaceutical development and manufacturing is a critical step to ensuring product safety. While this can be achieved using ELISA, mass spectrometry using the SCIEX TripleTOF® 6600 System is more specific and enables the identification and quantitation of each of the individual proteins present.

When developing new quantitative assays for Biotherapeutics, every biologic requires a specific sample prep strategy, which includes sourcing reagents and research protocols. However, as every bioanalytical lab knows all too well, it can also take up to two months to develop an optimized and robust LC-MS assay. For this reason, researchers understandably want an easier way to develop highly sensitive and specific assays for biotherapeutics and biosimilars to accelerate sample turnaround time.

From small ions like phosphate, herbicide degradation to metabolites, oligosaccharides, peptides, and proteins. How is your lab analyzing polar molecules? The reason I ask is there is a saying, if you have a charged or polar molecule, look to capillary electrophoresis (CE) first. While liquid chromatography (LC) is an ideal front-end separation tool for many types of molecules, as the following poster points out, “From Small to Very Large, Orthogonal, Sensitive Polar Molecule Analysis by CESI-MS,” there are some situations that call for CE over LC analysis. For those of you that are not familiar with CESI-MS, it is the combining of CE separation with electrospray ionization, into one dynamic process, within the same device.